• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Optimi Health Corp. - Common Shares (NQ:OPTH)

    3.490 -0.140 (-3.86%)
    Delayed Quote Updated: 12:21 PM EDT, Oct 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Optimi Health Corp. - Common Shares

    BioMedNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Plans Phase 3 MDMA-Assisted Therapy Trial for PTSD
    Via Investor Brand Network
    NetworkNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Plans Phase 2 Psilocybin Trial for Major Depressive Disorder
    Via Investor Brand Network
    InvestorNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Completes First Psilocybin Export to United Kingdom for Planned Phase 2 Trial
    Via Investor Brand Network
    Topics Supply Chain
    News headline image
    Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
    The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from... 
    From OPTIMI HEALTH CORP.
    Via GlobeNewswire
    BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Advances Ibogaine Drug Development Program
    Via Investor Brand Network
    News headline image
    Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
    From OPTIMI HEALTH CORP.
    Via GlobeNewswire
    BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Completes GMP Production Run of 5mg Psilocybin Drug Product
    Via Investor Brand Network
    News headline image
    Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
    From OPTIMI HEALTH CORP.
    Via GlobeNewswire
    NetworkNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Highlights Australia Psychedelic Therapy Expansion Following TGA Framework Update
    Via Investor Brand Network
    News headline image
    Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
    From OPTIMI HEALTH CORP.
    Via GlobeNewswire
    PsychedelicNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Featured in Diamond Equity Research Initiation Report Highlighting Commercial Psychedelics Opportunity
    Via Investor Brand Network
    InvestorNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Prices $15 Million Public Offering in Connection With Nasdaq Uplisting
    Via Investor Brand Network
    News headline image
    Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
    (May 20, 2026) - Optimi Health Corp. (NASDAQ:OPTH) (CSE:OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and 
    Via PressReach
    Topics Regulatory Compliance
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.